BCI Plans Across 10 Chinese Provinces All Target 2030, Only Zhejiang and Beijing Reimburse

Two sets of numbers are easy to misread. All of Jiangsu’s quantified targets hang on 2030. The 2027 section of its overall goals is almost entirely qualitative, its only hard figure being no fewer than two provincial clusters, and the real numbers sit at the end of its 14 tasks. Comparing them with other provinces’ 2027 targets overstates how aggressive Jiangsu is. Anhui’s clinical trial target is limited to invasive systems: no fewer than three approved invasive BCI trials by 2028, while a separate target of no fewer than five systems covers industrial, consumer and special-purpose uses and excludes medical ones. Anhui sets its near-term date at 2028 and phrases every target as a floor, which reads as cautious, but an invasive trial means a Class III device and open skull surgery, and three of them is not a low bar.

Provincial policy has accumulated quickly. Beijing moved first on 7 January 2025 and Shanghai followed three days later, the first Chinese provincial policies named for brain-computer interfaces rather than treating them as a sub-item under future industries or brain science. Sichuan and Shandong followed in May 2025. Two pushes then landed together: the seven-ministry implementation opinion dated 23 July 2025, and the Party plenum three months later that named BCI one of six future industries. Four jurisdictions had acted before those two dates; eight documents followed in the 13 months after, moving the rate from roughly one every six months to one every two. The rank of the issuing body rose in step. The first few came from provincial science or industry departments; Jiangxi, Tianjin, Anhui and Zhejiang then issued theirs through the general offices of their provincial governments; Shandong’s clinical translation plan carries 16 provincial signatures; and Guangdong’s came from the science committee office of the provincial Communist Party committee.

All dates given here are the dates the documents themselves carry, which differ from the publication dates used in much of the coverage. Zhejiang’s was signed off on 16 July 2026 and released on 12 August, almost a month apart. Anhui’s was signed off on 15 June and generally reported as 26 June. Ordering these documents by release date gets the sequence wrong.

Setting targets is only the first step. Between now and 2030 stand three gates — device registration, clinical adoption and payment — and what distinguishes these documents is which gate each province chose to work on.

The first gate is registration. On 22 March 2026 the world’s first invasive BCI product, Neuracle’s implantable system for compensating hand motor function, was approved for market, and its medical insurance code followed two days later. NeuroXess announced in July 2026 that its subdural flexible BCI had entered the special review procedure for innovative medical devices. The main provincial move at this gate is to shorten review timelines, and a visible contest has formed. On 7 July 2026 the Shandong Provincial Health Commission and 15 other bodies promised Class II device review within 90 working days, at the time the shortest in the country. Nine days later, on 16 July, Zhejiang offered 40 working days or fewer, plus a fast lane for listing medical consumables that closes within 10 working days of application. Class II devices are reviewed by provincial drug administrations, where the statutory limit usually exceeds 90 working days and actual time is often longer; for an early-stage company, cutting review from months to 40 working days speaks directly to cash flow. Neither commitment requires new budget or national-level authorisation, a provincial drug administration can make it alone, and it takes effect quickly and can be verified.

The second gate is clinical adoption, where the bottleneck is not approval but hospitals. A BCI product usually needs several hospitals enrolling at once to reach a workable sample size, yet under current practice each participating hospital’s ethics committee reviews the same protocol independently, so a project spanning five or six hospitals can lose six months to a year to ethics review alone. Jiangxi followed this one through. Its main document of November 2025 contained a single line about establishing mutual recognition of ethics review; six months later, on 26 May 2026, the Jiangxi Provincial Health Commission issued guidelines that turned that line into a procedure with dates on it. For multi-centre projects the lead institution’s ethics committee performs the first full review, and participating institutions are to complete their own within 10 working days of receiving a complete recognition package, examining only their local research conditions, staff qualifications and informed consent process. Invasive projects additionally go to a provincial medical ethics expert committee, which completes its check within 20 working days of accepting the materials and issues its opinion within a further seven. Adding a provincial layer for high-risk projects inserts one more step, and its function is to spread the liability, without which a participating institution’s ethics committee has little reason to rest on another institution’s conclusions.

Zhejiang addressed the hospitals’ willingness to take part. Its funding clause has four tiers, one of which gives research hospitals that engage deeply in preclinical work and help bring a product to market up to RMB 8 million per project, paid to the hospital and not to the company. Preclinical work requires biocompatibility testing, long-term implantation in large animals and reliability validation; hospitals spend staff time and beds on it and get neither papers nor product revenue in return. The same clause carries a provision that involves no money at all: beds used solely for clinical research are excluded from bed-efficiency, turnover, occupancy and DRG-based clinical performance assessment. Department assessments in public hospitals turn on exactly those measures, so the exemption removes an institutional obstacle. Shandong gave the whole clinical side its own document, led by the provincial health commission with 15 co-signing bodies, and its 14 measures include a clinical research alliance, a regularly published list of clinical needs, standardised procedures for subject screening and outcome assessment, multimodal standardised datasets and a provincial clinical database. Its slogan of validation in Shandong, application worldwide points at holding one link of the value chain through case volume and validation capacity. Splitting industry and clinical policy into two documents under two different lead agencies happens once among the 12.

The third gate is payment, currently the tightest. It starts with the pricing guideline for neurological services that the National Healthcare Security Administration issued in March 2025 under reference 医保价采函〔2025〕78号, which created three billable items — an invasive implantation fee, an invasive removal fee and a non-invasive fitting fee — for a technology that had not yet reached the market. The billing channel opened before any product was approved. Provinces followed quickly but priced very differently. Hubei was first, in document 鄂医保发〔2025〕19号 dated 30 March 2025, at RMB 6,552 per implantation, RMB 3,139 per removal and RMB 966 per fitting, all provincial ceilings. As the National Healthcare Security Administration put it in April 2026, most provinces have set government-guided prices, with invasive implantation clustered between RMB 6,000 and RMB 6,600 and non-invasive fitting around RMB 960.

Laying the official price tables side by side reveals something the coverage rarely shows: tiering by hospital grade is now common practice. Of 11 jurisdictions, only Beijing, Zhejiang, Hubei and Jiangxi use a single price; Guangdong publishes ceilings, Shanghai leaves pricing to hospitals, Jiangsu has only a draft, and the remaining four tier by hospital grade. Sichuan tiers most finely, across five grades, with invasive implantation falling from RMB 6,583 at a top-tier hospital to RMB 4,389 below grade 2B. The RMB 6,500 figure often quoted for a given province is usually just its top band, and what a patient actually pays depends on the grade of hospital. Beijing’s prices are the highest and the most detailed: document 京医保发〔2025〕15号 sets invasive implantation at RMB 7,980, prices semi-invasive procedures separately, and sets the non-invasive fitting fee at RMB 990 for the first session and RMB 330 for each session thereafter. Shanghai took a third route: document 沪医保价采发〔2025〕26号 created the three items but entered “determined by the hospital” in the price column, and stated that BCI services will not for now be covered by the city’s basic medical insurance. Creating the items, setting no price and covering nothing happens once among the provinces.

One phrase in these tables is regularly misread. Sichuan, Hainan, Qinghai and Xinjiang classify BCI charges as Category C, and the Jiangxi price table writes “self-paid” in the payment column; these mean the same thing. In Beijing’s own wording, Category A items carry no first-instance patient charge, Category B items carry 8% unless otherwise marked, and Category C items and the consumables used with them fall outside both basic medical insurance and work-injury insurance. Being listed as Category C sounds like insurance coverage and in fact leaves the patient paying in full, with the work-injury route closed as well. The 8% is Beijing’s figure; Zhejiang’s own document sets first-instance payment at 10%, and there is no national uniform rate.

Between pricing and reimbursement lies one more step. The operation performed in Wuhan in November 2025 was described as the country’s first BCI procedure billed at a government-guided price; according to the National Healthcare Security Administration, the patient’s costs were covered by research funding, so RMB 6,552 was the listed price rather than money the patient paid. As of August 2026, two jurisdictions have taken that further step. Zhejiang was first: document 浙医保发〔2025〕21号 brought the non-invasive fitting fee into basic medical insurance as Category B with a 10% patient share from 1 September 2025, limited to fitting an intelligent bionic limb, once per amputated limb. A stroke patient undergoing non-invasive rehabilitation training is outside that scope; an amputee fitting an intelligent bionic limb is covered for that fitting, but not for a second one on the same limb. Beijing brought all three items in as Category A with no first-instance patient charge, and its limit sits on the supply side: only Beijing Tiantan Hospital, Xuanwu Hospital, Peking University First Hospital and Peking Union Medical College Hospital may provide the service, and only at grade-3 rates. What the two have in common is that neither covers the largest cost. What actually deters patients is the invasive procedure plus the device, and no province reimburses that today.

Beyond the policy texts, clinical and industrial reality reads differently. On the clinical side the word is still “first”. Shandong’s first invasive BCI operation, on a patient with high-level quadriplegia, took place in July 2026 according to CCTV; the Inner Mongolia Autonomous Region’s first BCI ward opened in Hohhot that same month; and Shanghai issued its first BCI prescription in July 2026 according to The Paper. On the technical side there has been real movement. In July 2026 Zhejiang Provincial People’s Hospital performed China’s first implantation of a 320-resolution visual BCI, restoring visual function to a patient who had been blind for 20 years. In June 2026, in the IMIE intelligent retina trial at Xiangya Hospital of Central South University, a totally blind patient reached a best corrected acuity of 0.1 after surgery. Both echo the Shanghai promise to partially restore vision to blind patients by 2030; with most targets still on paper, this one has something to show.

Four years separate the first operation, first prescription and first ward of mid-2026 from the 3,000 procedures, 200 wards and RMB 10 billion cluster promised for 2030. The policy instruments have grown noticeably better aimed: shortened device review answers the first gate, mutual recognition of ethics review and the bed-assessment exemption answer the second, price listing and insurance coverage answer the third, all of which is more substantial than the stage 18 months ago when the documents talked only about output value and platforms. The sameness remains, with innovation platforms, tiered company support, application scenarios, investment funds and talent programmes repeated almost line for line across the 11 primary documents. The uncertainty is in execution. What keeps quality up under a 40-working-day review promise, whether 10-working-day mutual recognition survives contact with participating institutions, and whether insurance can widen from a limit as narrow as one fitting per amputated limb to the invasive procedure itself are questions none of the 12 documents answer; only the next four years will.

Table 1. The 12 provincial BCI policy documents

Table 2. Core quantified targets by jurisdiction

Table 3. Service pricing and insurance coverage

The three billable items derive from the pricing guideline for neurological services issued by the National Healthcare Security Administration in March 2025 under reference 医保价采函〔2025〕78号. The guideline defines a child as six years old or younger and requires a paediatric surcharge on surgical items, with the rate or amount set locally. This table covers provincial-level pricing only. Inner Mongolia is not listed: the regional healthcare security administration has published no BCI price document, and only the Hohhot municipal bureau issued one, on 8 August 2025 and effective 15 August.

A few billing rules are worth adding. Beijing prices semi-invasive (epidural) procedures separately at RMB 4,800 for placement and RMB 1,500 for removal, and covers all three items under work-injury insurance as well, but limits them to Beijing Tiantan Hospital, Xuanwu Hospital, Peking University First Hospital and Peking Union Medical College Hospital, and to grade-3 rates. Zhejiang excludes single-use cortical and depth electrodes from the implantation fee, allowing them to be sold separately at cost with no mark-up, and Hubei’s table says the same for the separately billable BCI system. Both Jiangxi and Zhejiang deduct RMB 30 where the required EEG, neural and EMG fitting data are not uploaded, using price as a lever to accumulate data. A rule against billing implantation and removal in the same operation appears in the tables of Jiangxi, Zhejiang, Shanghai, Xinjiang, Hubei and Hainan. Hainan is the only province to use two paediatric rates in one document, 30% on implantation and 15% on removal. The non-invasive fitting fee generally carries no paediatric surcharge.

For 10 of the 11 jurisdictions in this table, the prices, paediatric surcharges and payment categories come from the provincial documents themselves and their annexes: Beijing 京医保发〔2025〕15号, Shanghai 沪医保价采发〔2025〕26号, Zhejiang 浙医保发〔2025〕14号 and 浙医保发〔2025〕21号, Hubei 鄂医保发〔2025〕19号, Sichuan 川医保办发〔2025〕29号, Hainan 琼医保〔2025〕225号, Qinghai 青医保局发〔2025〕46号, Xinjiang 新医保规〔2025〕13号 and Guangdong 粤医保发〔2025〕27号. The Jiangsu figures of RMB 6,600, RMB 3,200 and RMB 966 come from a draft the provincial healthcare security administration posted for one week of comment on 29 July 2025, with no formal pricing document since. Its formal document implementing the national guideline, 苏医保发〔2025〕46号, returns no mention of brain-computer interfaces across its full text and ten annexes, and the three code positions the national numbering reserves for BCI are empty in the Jiangsu table.